Latest news from Albert Einstein College of Medicine and Montefiore Health System on Newswise en-us Copyright 2024 Newswise 115 31 / /images/newswise-logo-rss.gif /articles/5-minute-test-leads-to-better-care-for-people-with-dementia-in-the-primary-care-setting/?sc=rsin /articles/5-minute-test-leads-to-better-care-for-people-with-dementia-in-the-primary-care-setting/?sc=rsin Tue, 04 Jun 2024 05:00:00 EST The underdiagnosis of dementia, especially among Black and Hispanic patients, is a long-standing challenge in medicine. Albert Einstein College of Medicine and Montefiore Health System /articles/physician-scientists-underrepresented-in-medicine-to-conduct-health-equity-research-at-montefiore-and-einstein/?sc=rsin /articles/physician-scientists-underrepresented-in-medicine-to-conduct-health-equity-research-at-montefiore-and-einstein/?sc=rsin Tue, 06 Feb 2024 09:30:26 EST Montefiore Health System and Albert Einstein College of Medicine have been awarded a $1.5 million National Institutes of Health grant to provide advanced research training to post-graduate trainees from groups that are underrepresented in medicine and have research interests in heart, lung, blood, and sleep disorders. Over five years, nine researchers will receive intense research training and robust mentorship from almost 30 established, senior investigators across Montefiore and Einstein. Albert Einstein College of Medicine and Montefiore Health System /articles/world-renowned-scientist-and-researcher-yaron-tomer-md-named-the-marilyn-and-stanley-m-katz-dean-at-einstein/?sc=rsin /articles/world-renowned-scientist-and-researcher-yaron-tomer-md-named-the-marilyn-and-stanley-m-katz-dean-at-einstein/?sc=rsin Fri, 08 Sep 2023 09:30:40 EST Yaron Tomer, MD, has been named the Marilyn and Stanley M. Katz Dean at the Albert Einstein College of Medicine, effective October 2nd, 2023. Following a comprehensive national search, Dr. Tomer stood out as the clear choice to lead the College of Medicine amongst a group of highly accomplished and distinguished candidates. Albert Einstein College of Medicine and Montefiore Health System /articles/edward-chu-m-d-m-m-s-to-lead-cancer-medicine-at-albert-einstein-college-of-medicine-and-montefiore-health-system/?sc=rsin /articles/edward-chu-m-d-m-m-s-to-lead-cancer-medicine-at-albert-einstein-college-of-medicine-and-montefiore-health-system/?sc=rsin Wed, 22 Jul 2020 10:30:04 EST Albert Einstein College of Medicine and Montefiore Health System today announced that Edward Chu, M.D., M.M.S., has been named director of the National Cancer Institute-designated Albert Einstein Cancer Center; vice president for cancer medicine at Montefiore Medicine; professor of medicine and of molecular pharmacology; and will hold the Carol and Roger Einiger Professorship of Cancer Medicine at Einstein. In these roles, Dr. Chu will unite Einstein and Montefiore's cancer programs into a fully integrated research and clinical enterprise. The appointment will be effective October 1, 2020. Albert Einstein College of Medicine and Montefiore Health System /articles/common-blood-test-identifies-benefits-and-risks-of-steroid-treatment-in-covid-19-patients/?sc=rsin /articles/common-blood-test-identifies-benefits-and-risks-of-steroid-treatment-in-covid-19-patients/?sc=rsin Wed, 22 Jul 2020 05:00:00 EST A new study led by Albert Einstein College of Medicine and Montefiore Health System confirms the findings of the large scale British trial of steroid use for COVID-19 patients and advances the research by answering several key questions: Which patients are most likely to benefit from steroid therapy? Could some of them be harmed? Can other formulations of steroids substitute for the agent studied in the British trial? The research was published today in the Journal of Hospital Medicine. Albert Einstein College of Medicine and Montefiore Health System /articles/novel-therapy-for-acute-migraine-shows-promise-in-phase-3-clinical-trial/?sc=rsin /articles/novel-therapy-for-acute-migraine-shows-promise-in-phase-3-clinical-trial/?sc=rsin Wed, 10 Jul 2019 17:00:00 EST A drug belonging to a new generation of acute migraine headache treatments was found to eliminate pain and reduce bothersome symptoms for people with migraine in a large-scale trial reported in the July 11 issue of The New England Journal of Medicine. The drug, rimegepant, is awaiting U.S. Food and Drug Administration approval and may offer advantages over currently available migraine medications. The study was led by researchers at Albert Einstein College of Medicine and Montefiore Health System. Albert Einstein College of Medicine and Montefiore Health System